ArticleMedical journal of the Islamic Republic of Iran2025
The Role of Medications in Enhancing Patients' Overall Well-being and Quality of Life in Coronary Slow Flow syndrome: A Randomized Controlled Trial.
Article in Medical journal of the Islamic Republic of Iran, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary slow flow syndrome or phenomenon (CSFP) is a coronary artery disease that may cause cardiac ischemia, symptoms, and related complications. This study, conducted as a randomized controlled trial, assessed and compared the effects of a treatment plan comprising aspirin, statin, nitrate, and Nicorandil on the quality of life of patients with CSFP. Methods: Out of 963 patients who underwent coronary angiography at Booalisina University Hospital in Qazvin, 52 individuals diagnosed with primary CSFP were enrolled in the study. They were randomly divided into two groups, with one receiving a three-drug treatment with 80 mg of aspirin, 20 mg of atorvastatin daily, and 2.6 mg of nitroglycerin every 12 hours (26 patients) and in the second group plus nicorandil 10 mg every 12 hours (26 patients). After two months, the patient's QOL was evaluated and compared using McNew's quality of life questionnaire. The SPSS version 16 software was used for data analysis. Results: In both groups, after two months, the QOL scores in physical, emotional, social, and overall ( Conclusion: A combination therapy of aspirin, atorvastatin, and nitrates has been demonstrated to significantly improve the quality of life in patients with Coronary Slow Flow Phenomenon (CSFP). However, the addition of nicorandil to this regimen does not provide significant further improvement, according to present findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.